Summit Therapeutics (SMMT) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Summit Therapeutics (NASDAQ: SMMT) recently:

• 5/4/2026 – Summit Therapeutics had its price target lowered by HC Wainwright from $30.00 to $23.00. They now have a “buy” rating on the stock.
• 5/2/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/1/2026 – Summit Therapeutics had its price target lowered by Piper Sandler from $17.00 to $16.00. They now have a “neutral” rating on the stock.
• 4/21/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Summit Therapeutics is now covered by Citigroup Inc.. They set a “buy” rating on the stock.
• 4/8/2026 – Summit Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $45.00 price target on the stock.
• 3/25/2026 – Summit Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/16/2026 – Summit Therapeutics was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $15.00 price target on the stock, down from $42.00.

Summit Therapeutics plc is a clinical?stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life?threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.